Bioidentical Hormones Market – Global Industry Analysis and Forecast (2022-2027)

Bioidentical Hormones Market is expected to grow at a CAGR of 5.29% during the forecast period. Bioidentical Hormones Market is expected to reach US$ 10.45 Bn. by 2027. The report includes an analysis of the impact of COVID-19 lockdown on the revenue of market leaders, followers, and disruptors. Since the lockdown was implemented differently in various regions and countries; the impact of the same is also seen differently by regions and segments. The report has covered the current short-term and long-term impact on the market, and it would help the decision-makers to prepare the outline and strategies for companies by region.

Bioidentical Hormones Market

To know about the Research Methodology:- Request Free Sample Report

Bioidentical Hormones Market Dynamics:

Bioidentical hormones are hormones that are chemically identical as those that the body produces. These hormones are used by women in Hormone Replacement Therapy (HRT) to ease the menopause symptoms such as hot flashes, reduced sex drive, vaginal dryness, night sweats, weight gain, fatigue, and mood change. Rising screening tests for growth hormone deficiency analysis is majorly expected to drive the market growth. Improved screening for growth hormone deficiency using logical analysis data, worldwide rising female geriatric population, and growing awareness about technology related to bioidentical hormones therapy are expected to fuel the demand for bioidentical hormones in near future. The presence of alternative treatments for HRT is anticipated to restrain the market growth in over the forecast period. Alternatives to HRT such as tibolone, antidepressants, clonidine, and herbal remedies can affect the adoption of HRT treatments; hence, this is anticipated to hinder the market growth in the near future.

Bioidentical Hormones Market Segment Analysis:

The estrogen segment is expected to contribute a major market share over the forecast period due to abundant sources of plant estrogens coupled with rising demand for estrogen hormones such as estrone, estradiol, and estriol during HRT. The tablet and capsule segment is expected to lead the market over the forecast period due to rising preference from patients towards convenient dosage form and ease of administration.

Bioidentical Hormones Market Regional Insights:

North America is expected to contribute substantial market share over next ten years owing to a surge in the number of HRTs, higher spending on healthcare, rapid uptake of bioidentical hormone products in the U.S., and the presence of major market players in the region.

Bioidentical Hormones Market Research Methodology:

The market is estimated by triangulation of data points obtained from various sources and feeding them into a simulation model created individually for each market. The data points are obtained from paid and unpaid sources along with paid primary interviews with key opinion leaders (KOLs) in the market. KOLs from both, demand and supply sides were considered while conducting interviews to get an unbiased idea of the market. This exercise was done at a country level to get a fair idea of the market in countries considered for this study. Later this country-specific data was accumulated to come up with regional numbers and then arrive at the global market value for the bioidentical hormones market.

Bioidentical Hormones Market, Key Highlights:

• Bioidentical Hormones Market analysis and forecast, in terms of value. • Comprehensive study and analysis of market drivers, restraints and opportunities influencing the growth of the Bioidentical Hormones Market • Bioidentical Hormones Market segmentation on the basis of type, source, end-user, and region (country-wise) has been provided. • Bioidentical Hormones Market strategic analysis with respect to individual growth trends, future prospects along with the contribution of various sub-market stakeholders have been considered under the scope of study. • Bioidentical Hormones Market analysis and forecast for five major regions namely North America, Europe, Asia Pacific, the Middle East & Africa (MEA) and Latin America along with country-wise segmentation. • Profiles of key industry players, their strategic perspective, market positioning and analysis of core competencies are further profiled. • Competitive developments, investments, strategic expansion and competitive landscape of the key players operating in the Bioidentical Hormones Market are also profiled. The report has considered the base year of 2021 and past four years trend. 2021 figures are at actuals, however due to different dynamics of year 2021, market forecast is not only dependent upon 2021, but on the basis of 2017-2021.

Bioidentical Hormones Market Report Scope: Inquire before buying

Global Bioidentical Hormones Market
Report Coverage Details
Base Year: 2021 Forecast Period: 2022-2027
Historical Data: 2017 to 2021 Market Size in 2021: US$ 7.67  Bn.
Forecast Period 2022 to 2027 CAGR: 5.29% Market Size in 2027: US$ 10.45 Bn.
Segments Covered: by Type • Estrogen • Progesterone • Testosterone • Other
by Product Type • Tablet & Capsule • Cream & Gel • Patch & Implant • Injectable • Other
by End-use • Hospital & Clinic • Academic & Research • Other

Bioidentical Hormones Market, by Region

• North America • U.S. • Canada • Europe • UK • Germany • France • Italy • Spain • Rest of Europe • Asia Pacific • Japan • China • India • Rest of Asia Pacific • Latin America • Brazil • Mexico • Rest of Latin America • MEA • South Africa • Saudi Arabia • Rest of MEA

Bioidentical Hormones Market, Geographic Analysis:

• Breakdown of North America Bioidentical Hormones market • Breakdown of Europe Bioidentical Hormones market • Breakdown of Asia Pacific Bioidentical Hormones market • Breakdown of Latin America Bioidentical Hormones market • Breakdown of MEA Bioidentical Hormones market

Bioidentical Hormones Market, Key Players:

BioTE Medical • NutraMarks, Inc. • SottoPelle • Advantage Pharmaceuticals, Inc. • Bravado Labs • Full Life Wellness Center • Neuva Aesthetics • Defy Medical • Biostation • United Pharmacy, LLC • TherapeuticsMD, Inc • NOVO NORDISK A/S • BAYER AG • Merck KgaA • Pfizer Inc. • Allergan • GeneScience Pharmaceuticals Co., Ltd. • SUPREMA. • INMODE • Noven Pharmaceuticals, Inc. • Defy Medical Frequently Asked Questions: 1. Which region has the largest share in Global Bioidentical Hormones Market? Ans: North America region held the highest share in 2021. 2. What is the growth rate of Global Bioidentical Hormones Market? Ans: The Global Bioidentical Hormones Market is expected to grow at a CAGR of 5.29% during forecasting period 2022-2027. 3. What is scope of the Global Bioidentical Hormones market report? Ans: Global Bioidentical Hormones Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period. 4. Who are the key players in Global Bioidentical Hormones market? Ans: The important key players in the Global Bioidentical Hormones Market are – BioTE Medical, NutraMarks, Inc., SottoPelle, Advantage Pharmaceuticals, Inc., Bravado Labs, Full Life Wellness Center, Neuva Aesthetics, Defy Medical, Biostation, United Pharmacy, LLC, TherapeuticsMD, Inc, NOVO NORDISK A/S, BAYER AG, and Merck KgaA. 5. What is the study period of this market? Ans: The Global Bioidentical Hormones Market is studied from 2021 to 2027.

Bioidentical Hormones Market

1. EXECUTIVE SUMMARY 2. RESEARCH METHODOLOGY 2.1. Market Definition 2.2. Market Scope 2.3. Data Sources 3. MARKET VARIABLES & SCOPE 3.1. Market Segmentation & Scope 3.2. Market Driver Analysis 3.3. Market Restraint Analysis 3.4. Penetration & Growth Prospect Mapping 3.5. Market SWOT Analysis, By Factor (political & legal, economic, and technological) 3.6. Porter’s Five Forces Industry Analysis 3.7. Market Value Chain Analysis 4. TYPE ESTIMATES & TREND ANALYSIS (2021-2027) 4.1. Bioidentical Hormones Market: Type Movement Analysis 4.2. Estrogen 4.2.1. Estrogen market, 2021-2027 (USD million) 4.3. Progesterone 4.3.1. Progesterone market, 2021-2027 (USD million) 4.4. Testosterone 4.4.1. Testosterone market, 2021-2027 (USD million) 4.5. Other 4.5.1. Other market, 2021-2027 (USD million) 5. PRODUCT TYPE ESTIMATES & TREND ANALYSIS (2021-2027) 5.1. Bioidentical Hormones Market: Type Movement Analysis 5.2. Tablet & Capsule 5.2.1. Tablet & capsule market, 2021-2027 (USD million) 5.3. Cream & Gel 5.3.1. Cream & gel market, 2021-2027 (USD million) 5.4. Patch & Implant 5.4.1. Patch & implant market, 2021-2027 (USD million) 5.5. Injectable 5.5.1. Injectable market, 2021-2027 (USD million) 5.6. Other 5.6.1. Other market, 2021-2027 (USD million) 6. END-USE ESTIMATES & TREND ANALYSIS (2021-2027) 6.1. Bioidentical Hormones Market: End-use Movement Analysis 6.2. Hospital & Clinic 6.2.1. Hospital & clinic market, 2021-2027 (USD million) 6.3. Academic & Research 6.3.1. Academic & research market, 2021-2027 (USD million) 6.4. Other 6.4.1. Other market, 2021-2027 (USD million) 7. REGIONAL ESTIMATES & TREND ANALYSIS BY TYPE, PRODUCT TYPE, AND END-USE, (2021-2027) 7.1. Bioidentical Hormones Market Share By Region, 2021 & 2027 7.2. North America 7.2.1. North America bioidentical hormones market, 2021-2027 (USD million) 7.2.2. U.S. 7.2.2.1. U.S. bioidentical hormones market, 2021-2027 (USD million) 7.2.3. Canada 7.2.3.1. Canada bioidentical hormones market, 2021-2027 (USD million) 7.3. Europe 7.3.1. Europe bioidentical hormones market, 2021-2027 (USD million) 7.3.2. UK 7.3.2.1. UK bioidentical hormones market, 2021-2027 (USD million) 7.3.3. Germany 7.3.3.1. Germany bioidentical hormones market, 2021-2027 (USD million) 7.3.4. France 7.3.4.1. France bioidentical hormones market, 2021-2027 (USD million) 7.3.5. Italy 7.3.5.1. Italy bioidentical hormones market, 2021-2027 (USD million) 7.3.6. Spain 7.3.6.1. Spain bioidentical hormones market, 2021-2027 (USD million) 7.3.7. Rest of Europe 7.3.7.1. Rest of Europe bioidentical hormones market, 2021-2027 (USD million) 7.4. Asia Pacific 7.4.1. Asia Pacific bioidentical hormones market, 2021-2027 (USD million) 7.4.2. Japan 7.4.2.1. Japan bioidentical hormones market, 2021-2027 (USD million) 7.4.3. China 7.4.3.1. China bioidentical hormones market, 2021-2027 (USD million) 7.4.4. India 7.4.4.1. India bioidentical hormones market, 2021-2027 (USD million) 7.4.5. Rest of Asia Pacific 7.4.5.1. Rest of Asia Pacific bioidentical hormones market, 2021-2027 (USD million) 7.5. Latin America 7.5.1. Latin America bioidentical hormones market, 2021-2027 (USD million) 7.5.2. Brazil 7.5.2.1. Brazil bioidentical hormones market, 2021-2027 (USD million) 7.5.3. Mexico 7.5.3.1. Mexico bioidentical hormones market, 2021-2027 (USD million) 7.5.4. Rest of Latin America 7.5.4.1. Rest of Latin America bioidentical hormones market, 2021-2027 (USD million) 7.6. MEA 7.6.1. MEA bioidentical hormones market, 2021-2027 (USD million) 7.6.2. South Africa 7.6.2.1. South Africa bioidentical hormones market, 2021-2027 (USD million) 7.6.3. Saudi Arabia 7.6.3.1. Saudi Arabia bioidentical hormones market, 2021-2027 (USD million) 7.6.4. Rest of MEA 7.6.4.1. Rest of MEA bioidentical hormones market, 2021-2027 (USD million) 8. MARKET COMPETITION ANALYSIS 8.1. Strategy Framework 8.2. Company Profiles 8.2.1. BioTE Medical 8.2.1.1. Company Overview 8.2.1.2. Financial Performance 8.2.1.3. Product Benchmarking 8.2.1.4. Strategic Initiatives 8.2.2. NutraMarks, Inc. 8.2.2.1. Company Overview 8.2.2.2. Financial Performance 8.2.2.3. Product Benchmarking 8.2.2.4. Strategic Initiatives 8.2.3. SottoPelle 8.2.3.1. Company Overview 8.2.3.2. Financial Performance 8.2.3.3. Product Benchmarking 8.2.3.4. Strategic Initiatives 8.2.4. Advantage Pharmaceuticals, Inc. 8.2.4.1. Company Overview 8.2.4.2. Financial Performance 8.2.4.3. Product Benchmarking 8.2.4.4. Strategic Initiatives 8.2.5. Bravado Labs 8.2.5.1. Company Overview 8.2.5.2. Financial Performance 8.2.5.3. Product Benchmarking 8.2.5.4. Strategic Initiatives 8.2.6. Full Life Wellness Center 8.2.6.1. Company Overview 8.2.6.2. Financial Performance 8.2.6.3. Product Benchmarking 8.2.6.4. Strategic Initiatives 8.2.7. Neuva Aesthetics 8.2.7.1. Company Overview 8.2.7.2. Financial Performance 8.2.7.3. Product Benchmarking 8.2.7.4. Strategic Initiatives 8.2.8. Defy Medical 8.2.8.1. Company Overview 8.2.8.2. Financial Performance 8.2.8.3. Product Benchmarking 8.2.8.4. Strategic Initiatives 8.2.9. Biostation 8.2.9.1. Company Overview 8.2.9.2. Financial Performance 8.2.9.3. Product Benchmarking 8.2.9.4. Strategic Initiatives 8.2.10. United Pharmacy, LLC 8.2.10.1. Company Overview 8.2.10.2. Financial Performance 8.2.10.3. Product Benchmarking 8.2.10.4. Strategic Initiatives 8.2.11. TherapeuticsMD, Inc 8.2.11.1. Company Overview 8.2.11.2. Financial Performance 8.2.11.3. Product Benchmarking 8.2.11.4. Strategic Initiatives 8.2.12. NOVO NORDISK A/S 8.2.12.1. Company Overview 8.2.12.2. Financial Performance 8.2.12.3. Product Benchmarking 8.2.12.4. Strategic Initiatives 8.2.13. BAYER AG 8.2.13.1. Company Overview 8.2.13.2. Financial Performance 8.2.13.3. Product Benchmarking 8.2.13.4. Strategic Initiatives 8.2.14. Merck KgaA 8.2.14.1. Company Overview 8.2.14.2. Financial Performance 8.2.14.3. Product Benchmarking 8.2.14.4. Strategic Initiatives 8.2.15. Pfizer Inc. 8.2.15.1. Company Overview 8.2.15.2. Financial Performance 8.2.15.3. Product Benchmarking 8.2.15.4. Strategic Initiatives 8.2.16. Allergan 8.2.16.1. Company Overview 8.2.16.2. Financial Performance 8.2.16.3. Product Benchmarking 8.2.16.4. Strategic Initiatives 8.2.17. GeneScience Pharmaceuticals Co., Ltd. 8.2.17.1. Company Overview 8.2.17.2. Financial Performance 8.2.17.3. Product Benchmarking 8.2.17.4. Strategic Initiatives 8.2.18. SUPREMA. 8.2.18.1. Company Overview 8.2.18.2. Financial Performance 8.2.18.3. Product Benchmarking 8.2.18.4. Strategic Initiatives 8.2.19. INMODE 8.2.19.1. Company Overview 8.2.19.2. Financial Performance 8.2.19.3. Product Benchmarking 8.2.19.4. Strategic Initiatives 8.2.20. Noven Pharmaceuticals, Inc. 8.2.20.1. Company Overview 8.2.20.2. Financial Performance 8.2.20.3. Product Benchmarking 8.2.20.4. Strategic Initiatives 8.2.21. Defy Medical 8.2.21.1. Company Overview 8.2.21.2. Financial Performance 8.2.21.3. Product Benchmarking 8.2.21.4. Strategic Initiatives

About This Report

Report ID 1854
Category Healthcare
Published Date July 2019
Updated Date Apr 2022
Contact Us